Fulcrum Therapeutics

(NASDAQ) FULC

Current Price$7.29

Market Cap$467.10M

Since IPO (2019)-48%

5 Year-33%

1 Year+30%

1 Month-11%

Fulcrum Therapeutics Financials at a Glance

Market Cap

$467.10M

Revenue (TTM)

$0.00

Net Income (TTM)

$76.12M

EPS (TTM)

$-1.15

P/E Ratio

-6.11

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Price

$7.29

Volume

14,156

Open

$7.29

Price

$7.29

Volume

14,156

Open

$7.29

Previous Close

$7.01

Daily Range

$7.29 - $7.29

52-Week Range

$5.37 - $15.74

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Price

$7.29

Volume

14,156

Open

$7.29

Previous Close

$7.01

Daily Range

$7.29 - $7.29

52-Week Range

$5.37 - $15.74

FULC News

FULC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fulcrum Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Alexander C. Sapir, MBA

Website

www.fulcrumtx.com

Headquarters

Cambridge, MA 02139, US

FULC Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-27%

Return on Capital

-26%

Return on Assets

-22%

Earnings Yield

-16.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$467.10M

Shares Outstanding

66.63M

Volume

14.16K

Avg. Volume

1.06M

Financials (TTM)

Gross Profit

$1.39M

Operating Income

$84.77M

EBITDA

$73.49M

Operating Cash Flow

$60.06M

Capital Expenditure

$314.00K

Free Cash Flow

$60.38M

Cash & ST Invst.

$352.31M

Total Debt

$6.44M

Fulcrum Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$338.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$467.10M

N/A

Market Cap/Employee

$10.38M

N/A

Employees

N/A

Net Income

$18.89M

-7.0%

EBITDA

$21.85M

-9.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$327.45M

+49.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$3.41M

-41.9%

Short Term Debt

$2.46M

+9.9%

Return on Assets

-21.95%

N/A

Return on Invested Capital

-25.69%

N/A

Free Cash Flow

$18.76M

-22.9%

Operating Cash Flow

$18.75M

-22.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NGNENeurogene Inc.

NGNENeurogene Inc.$30.78+0.00%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$3.55+1.43%

OCGNOcugen, Inc.

OCGNOcugen, Inc.$1.57+3.97%

NMRANeumora Therapeutics, Inc. Common Stock

NMRANeumora Therapeutics, Inc. Common Stock$1.82-0.55%

BCYCBicycle Therapeutics plc

BCYCBicycle Therapeutics plc$4.83+0.42%

CMPXCompass Therapeutics, Inc.

CMPXCompass Therapeutics, Inc.$1.79-2.19%

LXRXLexicon Pharmaceuticals, Inc.

LXRXLexicon Pharmaceuticals, Inc.$2.01+0.64%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

IRENIren

IRENIren$61.20+0.08%

NOKNokia

NOKNokia$12.82+0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.62+0.08%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.57-0.07%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.35+0.01%

Questions About FULC

What is the current price of Fulcrum Therapeutics?

Fulcrum Therapeutics is trading at $7.29 per share.

What is the 52-week range for Fulcrum Therapeutics?

Over the past 52 weeks, Fulcrum Therapeutics has traded between $5.37 and $15.74.

How much debt does Fulcrum Therapeutics have?

As of the most recent reporting period, Fulcrum Therapeutics reported total debt of $5.87M.

How much cash does Fulcrum Therapeutics have on hand?

Fulcrum Therapeutics reported $50.26M in cash and cash equivalents in its most recent financial results.

What is Fulcrum Therapeutics’s dividend yield?

Fulcrum Therapeutics does not currently have a dividend yield.

Fulcrum Therapeutics

Fulcrum Therapeutics Financials at a Glance

FULC News

2 Soaring Biotech Stocks With More Fuel in the Tank

Why Fulcrum Therapeutics Popped Again on Tuesday

Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today

FULC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Fulcrum Therapeutics

FULC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Fulcrum Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About FULC

What is the current price of Fulcrum Therapeutics?

What is the 52-week range for Fulcrum Therapeutics?

How much debt does Fulcrum Therapeutics have?

How much cash does Fulcrum Therapeutics have on hand?

What is Fulcrum Therapeutics’s dividend yield?

Premium Investing Services